Contineum Therapeutics Business Summary

Contineum Therapeutics, Inc. (CTNM) is a clinical-stage biopharmaceutical company that generates revenue primarily through strategic licensing agreements, upfront payments, and milestone-based fees, most notably from its high-profile collaboration with Johnson & Johnson (Janssen) for the development of PIPE-307. The company operates within the neuroscience, inflammation, and immunology (NI&I) segments, focusing on internally discovered, oral small-molecule therapies. Its lead assets include PIPE-791, a brain-penetrant LPA1 receptor antagonist targeting idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis, and PIPE-307, a selective M1 receptor antagonist in Phase 2 trials for depression and relapsing-remitting MS. Contineum competes directly with clinical-stage peers such as Enliven Therapeutics (ELVN), Tyra Biosciences (TYRA), and Oruka Therapeutics (ORKA), positioning itself as a specialized developer of highly selective, brain-penetrant molecules that address biological pathways previously considered difficult to target. The leadership team is led by President and CEO Carmine Stengone, who previously served as CEO of Avelas Biosciences and held senior roles at Afraxis and Anadys Pharmaceuticals. The company was co-founded by Chief Scientific Officer Daniel S. Lorrain, Ph.D., an industry veteran with a pedigree from Amira Pharmaceuticals (acquired by BMS) and Merck. Other key executives include CFO Peter T. Slover, formerly of AnaptysBio, and Chief Medical Officer Timothy Watkins, M.D., who joined in 2025 from Gilead Sciences to spearhead late-stage clinical development. The company is backed by a sophisticated investor base including Hillhouse Capital and Point72 Asset Management, and its Board of Directors features prominent industry figures such as Sarah Boyce (CEO of Avidity Biosciences) and Chairman Evert Schimmelpennink.